GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aeolus Pharmaceuticals Inc (OTCPK:AOLS) » Definitions » Volatility

Aeolus Pharmaceuticals (Aeolus Pharmaceuticals) Volatility : N/A% (As of Jun. 08, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Aeolus Pharmaceuticals Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

Aeolus Pharmaceuticals does not have enough data to calculate Volatility.


Competitive Comparison of Aeolus Pharmaceuticals's Volatility

For the Drug Manufacturers - Specialty & Generic subindustry, Aeolus Pharmaceuticals's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aeolus Pharmaceuticals's Volatility Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aeolus Pharmaceuticals's Volatility distribution charts can be found below:

* The bar in red indicates where Aeolus Pharmaceuticals's Volatility falls into.



Aeolus Pharmaceuticals  (OTCPK:AOLS) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aeolus Pharmaceuticals  (OTCPK:AOLS) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Aeolus Pharmaceuticals Volatility Related Terms

Thank you for viewing the detailed overview of Aeolus Pharmaceuticals's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Aeolus Pharmaceuticals (Aeolus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.
Executives
John L Mcmanus officer: President and CEO C/O AEOLUS PHARMACEUTICALS, INC., 26361 CROWN VALLEY PARKWAY, SUITE 150, MISSION VIEJO CA 92691
Chris A Rallis director C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Amit Kumar director C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Joseph J Krivulka director C/O DANCE BIOPHARM INC., 150 NORTH HILL DRIVE, SUITE 24, BRISBANE CA 94005
David Cavalier director C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Michael E Lewis director C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Peter David Suzdak director 1204 MEADOWLARK DRIVE, TOWSON MD 21286
Russell Skibsted officer: Chief Financial Officer 15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Mark Lappe 10 percent owner 11622 EL CAMINO REAL, SUITE 100, SAN DIEGO CA 92130
Bvf Investments Llc 10 percent owner, other: Indirect Beneficial Owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp 10 percent owner, other: Indirect Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner, other: Indirect Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner, other: Indirect Beneficial Owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Biotechnology Value Fund L P 10 percent owner, other: Indirect Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jon Faiz Kayyem 10 percent owner 5964 LA PLACE COURT, CARLSBAD CA 92008

Aeolus Pharmaceuticals (Aeolus Pharmaceuticals) Headlines

From GuruFocus